Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Recombinant human cometin - Hoba Therapeutics

Next Previous
X
Search
Drug Profile

Recombinant human cometin - Hoba Therapeutics

Alternative Names: HB 097; Recombinant cometin - Hoba Therapeutics

Latest Information Update: 22 Oct 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Hoba Therapeutics
  • Class Neuroprotectants; Recombinant proteins
  • Mechanism of Action Nerve growth factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Hearing disorders
  • Discontinued Neuropathic pain

Most Recent Events

  • 22 Oct 2024 Preclinical trials in Hearing disorders in Denmark (Otic), prior to October 2024 (Hoba Therapeutics pipeline, October 2024)
  • 11 Dec 2023 Updated pharmacodynamics data from a preclinical trial in Hearing disorders released by Hoba Therapeutics
  • 24 Jul 2023 Preclinical development is ongoing for Hearing disorders in Denmark (Otic, Infusion) (Hoba Therapeutics pipeline, July 2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top